Bell R, Gallagher C J, Ford J, Malpas J S, Lister T A
Cancer Treat Rep. 1982 Feb;66(2):377-80.
Fifty-seven courses of cyclophosphamide (2.5-5.0 g/m2) and prednisolone (1.0 g/m2 x 5) were given to 22 patients with advanced stage IV non-Hodgkin's lymphoma of favorable histology. Six patients (27%) had a complete response (CR) (median duration, 10.1 months), and six (27%) had a partial response (median duration, 3.0 months). All patients in whom CR was achieved had a previous disease pattern of remission and relapse, and no patient refractory to previous therapy had a CR. This association of CR to disease pattern was statistically significant (P less than 0.0001). There was no difference in the survival of complete and partial responders. There was a trend to a higher response rate and statistically significant survival advantage (P less than 0.05) for patients with the nodular histologic types. The transient nature of response and the toxicity of the regimen, with four therapy-related deaths, render it unsuitable as routine therapy.
对22例组织学类型良好的晚期IV期非霍奇金淋巴瘤患者给予57个疗程的环磷酰胺（2.5 - 5.0 g/m²）和泼尼松龙（1.0 g/m²×5）治疗。6例患者（27%）达到完全缓解（CR）（中位持续时间为10.1个月），6例（27%）达到部分缓解（中位持续时间为3.0个月）。所有达到CR的患者既往都有缓解和复发的疾病模式，且既往治疗难治的患者均未达到CR。CR与疾病模式的这种关联具有统计学意义（P<0.0001）。完全缓解者和部分缓解者的生存率无差异。结节组织学类型的患者有更高的缓解率趋势和统计学上显著的生存优势（P<0.05）。缓解的短暂性以及该方案的毒性，导致4例与治疗相关的死亡，使其不适合作为常规治疗。
